Shionogi Acquires Tetra Therapeutics, Rights to Fragile X Treatment
Shionogi has acquired Tetra Therapeutics, the developer of the BPN14770 treatment candidate for fragile X syndrome and Alzheimer’s disease.| Fragile X News Today
Shionogi has acquired Tetra Therapeutics, the developer of the BPN14770 treatment candidate for fragile X syndrome and Alzheimer’s disease.| Fragile X News Today
